Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors

• Published in: Molecular imaging and biology Vol. 18; no. 3; pp. 446 - 453
• Main Authors: Lockhart, A. Craig, Liu, Yongjian, Dehdashti, Farrokh, Laforest, Richard, Picus, Joel, Frye, Jennifer, Trull, Lauren, Belanger, Stefanie, Desai, Madhuri, Mahmood, Syed, Mendell, Jeanne, Welch, Michael J., Siegel, Barry A.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2016; Springer Nature B.V
• Subjects: Adult; Aged; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing - adverse effects; Antibodies, Neutralizing - therapeutic use; Broadly Neutralizing Antibodies; Female; Humans; Imaging; Male; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Staging; Neoplasms - diagnostic imaging; Neoplasms - drug therapy; Neoplasms - pathology; Organometallic Compounds - adverse effects; Organometallic Compounds - pharmacokinetics; Organometallic Compounds - therapeutic use; Positron-Emission Tomography; Radiology; Radiometry; Receptors, Cell Surface; Research Article; Tomography, X-Ray Computed; Treatment Outcome; Human epidermal growth factor receptor 3; Patritumab; Cu]DOTA-patritumab; PET/CT; [; Phase 1; Dosimetry; Receptor occupancy; [64Cu]DOTA-patritumab
• ISSN: 1536-1632; 1860-2002
• DOI: 10.1007/s11307-015-0912-y

Purpose The purpose of this study was to evaluate the safety, dosimetry, and apparent receptor occupancy (RO) of [ 64 Cu]DOTA-patritumab, a radiolabeled monoclonal antibody directed against HER3/ERBB3 in subjects with advanced solid tumors. Procedures Dosimetry subjects ( n  = 5) received [ 64 Cu]DO...